Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

Distalmotion’s Dexter Robot receives CE Mark

8 Jan 2021 07:00

RNS Number : 9916K
Surgical Innovations Group PLC
08 January 2021
 

Surgical Innovations Group plc("Surgical Innovations", "SI" or the "Company")

 

Distalmotion's Dexter Robot receives CE Mark

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces that Distalmotion SA, a Swiss-based medical device company providing robotic surgery systems on a transparent and fair per-procedure cost ("Distalmotion"), has received European CE Mark for its 'Dexter' surgical robot. Manufactured in Switzerland, Dexter combines the affordability of laparoscopy with the benefits of robotic surgery to bring simplicity and versatility in minimally invasive surgical care. 

 

Elemental Healthcare Limited, a wholly owned SI subsidiary, has exclusive UK distribution rights for the Dexter Robot.

 

The European CE mark remains valid in the UK post Brexit.

 

Adam Power, SI Group Development Director, commented: "The UK minimally invasive surgical robot market has been dominated by a single, expensive and very complex robot for nearly two decades. Dexter is designed to integrate readily into existing laparoscopic procedures and its simplicity and versatility makes robotics accessible for a wider range of procedures. The regulatory approval of the Dexter operating robot now allows the introduction of a disruptive robotic model to UK healthcare. The ease of use, affordability and Swiss manufacturing excellence will be significant factors in the growth opportunity for this new robot."

 

Michael Friedrich, CEO, Distalmotion said: "Distalmotion are looking forward to some early successes in the important UK market with our partner, Elemental Healthcare. The NHS is especially appropriate for the Dexter strategic model of selling and we already have hospitals that are some way into the process of product acquisition."

 

 

For further information please contact:

 

Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Tel: 0113 230 7597

Charmaine Day, Co Sec & GFC

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell (Corporate Finance)

 

Rachel Hayes (Corporate Broking)

 

 

 

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or si@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part re-usable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

In addition, we design and develop medical devices for carefully selected OEM partners, and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

 

The Group currently employs approximately 100 people across two sites in the UK. Product design, engineering and manufacturing are carried out at the SI site in Yorkshire. Commercial activities including marketing, UK distribution and international sales and marketing are based at Elemental Healthcare in Berkshire.

 

Further information

Further details of the Group's businesses are available on the following websites:

www.sigroupplc.com

www.surginno.com 

www.elementalhealthcare.co.uk

To receive regular updates by email, please contact si@walbrookpr.com.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFLDLDIDIIL
Date   Source Headline
5th Jun 20267:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
21st Apr 20267:00 amRNSFinal Results
9th Apr 20267:00 amRNSNotice of Results and Investor Presentation
8th Jan 20267:00 amRNSChief Financial Officer update
18th Dec 20257:00 amRNSTrading Update
28th Nov 20257:00 amRNSNew LTIP & Grant of Options
29th Sep 20257:05 amRNSBoard Changes
29th Sep 20257:00 amRNSHalf-year Report
17th Sep 20253:15 pmRNSNotice of Results
27th Jun 20254:42 pmRNSResult of AGM
26th Jun 202511:36 amRNSWithdrawal of AGM Resolutions 9 and 10
4th Jun 20258:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
30th May 20257:00 amRNSFinal Results
10th Apr 20257:00 amRNSTrading update
1st Apr 202511:30 amRNSUpdate on timing of 2024 Full Year results
19th Feb 202510:11 amRNSHolding(s) in Company
17th Feb 20254:12 pmRNSHolding(s) in Company
12th Feb 20257:00 amRNSFY24 Trading Update & & Directorship Change
30th Sep 20247:00 amRNSHalf-year Report
10th Sep 20247:00 amRNSNotice of Results
27th Aug 20243:51 pmRNSHolding(s) in Company
27th Aug 20243:49 pmRNSHolding(s) in Company
19th Aug 20241:06 pmRNSHolding(s) in Company
19th Aug 20241:01 pmRNSHolding(s) in Company
29th Jul 202412:18 pmRNSHolding(s) in Company
25th Jul 20244:04 pmRNSHolding(s) in Company
17th Jun 20244:43 pmRNSResult of AGM
10th Jun 20247:00 amRNSDirectorate Change - Appointment of CFO
23rd May 20247:00 amRNSNotice of AGM and Posting of Annual Report
22nd Apr 20243:34 pmRNSHolding(s) in Company
19th Apr 20246:25 pmRNSHolding(s) in Company
18th Apr 20247:01 amRNSFinal Results
18th Apr 20247:00 amRNSNew exclusive UK distribution agreements secured
9th Apr 20247:00 amRNSDirectorate Change & Notice of Results
29th Jan 20247:00 amRNSYear-end 2023 Trading Update
19th Dec 20237:00 amRNSDirectorate Change
5th Dec 20237:00 amRNSDirectorate Change
19th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTrading Update and Notice of Results
27th Jun 202312:12 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement
26th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
25th May 202311:11 amRNSDirector/PDMR Shareholding - Replacement
25th May 20237:00 amRNSDirector/PDMR Shareholding
22nd May 20237:00 amRNSDirectorate changes and board succession planning
29th Mar 20237:00 amRNSFinal Results
3rd Mar 20237:00 amRNSNotice of Results and Investor Presentation
23rd Jan 20237:00 amRNSYear-end Trading Update
21st Sep 20227:00 amRNSHalf-year Report
2nd Sep 20227:00 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.